| Rank |
Title |
Journal |
Year |
PubWeight™‹?› |
|
1
|
The prognostic relevance of histological type in uterine sarcomas: a Cooperation Task Force (CTF) multivariate analysis of 249 cases.
|
Eur J Gynaecol Oncol
|
2002
|
1.03
|
|
2
|
Preoperative evaluation of D-dimer and CA 125 levels in differentiating benign from malignant ovarian masses.
|
Gynecol Oncol
|
1996
|
0.98
|
|
3
|
The relationship between postoperative decline of serum CA 125 levels and size of residual disease after initial surgery in patients with advanced ovarian cancer: a CTF study.
|
Gynecol Oncol
|
1996
|
0.97
|
|
4
|
The concomitant determination of different tumor markers in patients with epithelial ovarian cancer and benign ovarian masses: relevance for differential diagnosis.
|
Gynecol Oncol
|
1992
|
0.90
|
|
5
|
Serum levels of tumor necrosis factor (TNF), soluble receptors for TNF (55- and 75-kDa sTNFr), and soluble CD14 (sCD14) in epithelial ovarian cancer.
|
Gynecol Oncol
|
1995
|
0.90
|
|
6
|
Analysis of failures after negative second-look in patients with advanced ovarian cancer: an Italian multicenter study.
|
Gynecol Oncol
|
1998
|
0.89
|
|
7
|
Pretreatment plasma levels of fibrinopeptide-A (FPA), D-dimer (DD), and von Willebrand factor (vWF) in patients with operable cervical cancer: influence of surgical-pathological stage, tumor size, histologic type, and lymph node status.
|
Gynecol Oncol
|
1993
|
0.87
|
|
8
|
A comparison of pretreatment serum levels of four tumor markers in patients with endometrial and cervical carcinoma.
|
Eur J Gynaecol Oncol
|
1990
|
0.85
|
|
9
|
Preoperative serum antibodies against the p53 protein in patients with ovarian and endometrial cancer.
|
Anticancer Res
|
1997
|
0.85
|
|
10
|
Prothrombin fragment F1+2 and thrombin-antithrombin III complex (TAT) plasma levels in patients with gynecological cancer.
|
Gynecol Oncol
|
1996
|
0.83
|
|
11
|
Pretreatment plasma levels of fibrinopeptide-A (FPA), D-dimer (DD), and von Willebrand factor (vWF) in patients with ovarian carcinoma.
|
Gynecol Oncol
|
1994
|
0.83
|
|
12
|
Comparison of tumor-associated trypsin inhibitor (TATI) with CA125 as a marker for diagnosis and monitoring of epithelial ovarian cancer.
|
Scand J Clin Lab Invest Suppl
|
1991
|
0.80
|
|
13
|
Preoperative D-dimer plasma assay is not a predictor of clinical outcome for patients with advanced ovarian cancer.
|
Gynecol Oncol
|
1997
|
0.79
|
|
14
|
The clinical outcome of patients with stage Ia1 and Ia2 squamous cell carcinoma of the uterine cervix: a Cooperation Task Force (CTF) study.
|
Eur J Gynaecol Oncol
|
2003
|
0.78
|
|
15
|
Serum assay of soluble CD44 standard (sCD44-st), CD44 splice variant v5 (sCD44-v5), and CD44 splice variant v6 (sCD44-v6) in patients with epithelial ovarian cancer.
|
Anticancer Res
|
1998
|
0.78
|
|
16
|
Serum macrophage colony-stimulating factor (M-CSF) levels in patients with epithelial ovarian cancer.
|
Gynecol Oncol
|
1998
|
0.77
|
|
17
|
Elevated serum levels of neopterin and soluble interleukin-2 receptor in patients with ovarian cancer.
|
Gynecol Oncol
|
1994
|
0.77
|
|
18
|
A comparative evaluation of the ability of serum CA 125, CA 19-9, CA 15-3, CA 50, CA 72-4 and TATI assays in reflecting the course of disease in patients with ovarian carcinoma.
|
Eur J Gynaecol Oncol
|
1990
|
0.77
|
|
19
|
Serum CA125 assay at the time of relapse has no prognostic relevance in patients undergoing chemotherapy for recurrent ovarian cancer: a multicenter Italian study.
|
Int J Gynecol Cancer
|
1997
|
0.77
|
|
20
|
Serum levels of soluble receptors for tumor necrosis factor (p55 and p75 sTNFr) in endometrial cancer.
|
Anticancer Res
|
1996
|
0.76
|
|
21
|
The measurement of plasma D-dimer (DD) levels in the follow-up of patients with ovarian cancer.
|
Anticancer Res
|
1996
|
0.75
|
|
22
|
Evaluation of some hemostatic parameters in patients with cervical carcinoma.
|
Eur J Gynaecol Oncol
|
1990
|
0.75
|
|
23
|
Recurrence patterns in patients with early stage cervical cancer treated with radical hysterectomy and external pelvic irradiation.
|
Anticancer Res
|
1995
|
0.75
|
|
24
|
Hormone replacement therapy and gynecological cancer.
|
Anticancer Res
|
1998
|
0.75
|
|
25
|
Platinum compounds and paclitaxel in advanced epithelial ovarian cancer.
|
Anticancer Res
|
1998
|
0.75
|
|
26
|
Adjuvant treatment of early stage ovarian carcinoma.
|
Clin Exp Obstet Gynecol
|
1990
|
0.75
|
|
27
|
The serum assay of soluble CD44 standard (sCD44-st), CD44 splice variant 5 (sCD44-v5), and CD44 splice variant 6 (sCD44-v6) in patients with cervical cancer.
|
Anticancer Res
|
1998
|
0.75
|
|
28
|
Analysis of treatment failures in patients with early-stage uterine leiomyosarcoma.
|
Anticancer Res
|
1995
|
0.75
|
|
29
|
CA 195: a new monoclonal antibody-defined Lea blood group-related tumor marker in patients with epithelial ovarian cancer.
|
J Nucl Biol Med
|
1991
|
0.75
|
|
30
|
A comparison of the usefulness of serum measurements of CA 125, CA 50 and TATI in patients with malignant and benign gynecological pathology.
|
Eur J Gynaecol Oncol
|
1990
|
0.75
|